[Idiopathic hyperaldosteronism (IHA)].
Miyashita K, Itoh H, Nakao K.
Nihon Rinsho. 2006 May 28;Suppl 1:624-7.
The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y, Long T, Peng N, Zhen M, Ye Q, Zhang Z, He Y, Chen Z, Gan Y, Luo M, Li C, Liu Z, Guo M, Wang M, Luo X, Hu S, Liu L, Jiang T.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):171-182. doi: 10.1210/clinem/dgad421.
Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial.
Zhou L, Jiang Y, Zhang C, Su T, Jiang L, Zhou W, Zhong X, Wu L, Wang W.
Front Endocrinol (Lausanne). 2023 Apr 19;14:1124479. doi: 10.3389/fendo.2023.1124479. eCollection 2023.
Hyperaldosteronism in pregnancy.
Escher G.
Ther Adv Cardiovasc Dis. 2009 Apr;3(2):123-32. doi: 10.1177/1753944708100180. Epub 2009 Jan 26.
Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution.
Iwahashi N, Umakoshi H, Seki T, Gomez-Sanchez CE, Mukai K, Suematsu M, Umezawa Y, Oya M, Kosaka T, Seki M, Suzuki Y, Horiuchi Y, Ogawa Y, Nishimoto K.
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2439-2448. doi: 10.1210/clinem/dgac394.
Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.
Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE.
Hypertension. 2018 Oct;72(4):874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086.
Associations between thyroid function, thyroid diseases, and primary aldosteronism.
Maiturouzi M, Zhu Q, Zhang D, Luo Q, Wang M, Cai X, Heizhati M, Cai L, Wu T, Liu S, Dang Y, Aimudula A, Hong J, Li N.
Eur J Endocrinol. 2024 Aug 5;191(2):262-270. doi: 10.1093/ejendo/lvae087.
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Yoshimoto T, Kawashima J, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Miyauchi S, Kamemura K, Fukuoka T, Yamamoto K, Otsuki M, Suzuki T, Naruse M; JPAS Study Group.
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4456-4464. doi: 10.1210/jc.2018-00866.
Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.
Watanabe D, Morimoto S, Morishima N, Ichihara A.
Endocrine. 2024 Apr;84(1):245-252. doi: 10.1007/s12020-023-03627-w. Epub 2023 Dec 12.
Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial.
Dong H, Zou Y, He J, Deng Y, Chen Y, Song L, Xu B, Gao R, Jiang X.
Catheter Cardiovasc Interv. 2021 May 1;97 Suppl 2:976-981. doi: 10.1002/ccd.29554. Epub 2021 Feb 19.
